BioAgilytix Adds Extensive Capabilities with the Acquisition of MicroConstants and 360biolabs®️
As an independent bioanalytical testing industry leader, MicroConstants, now known as BioAgilytix San Diego, has been providing Good Laboratory Practice (GLP) compliant services for decades. Headquartered in San Diego, MicroConstants offers services such as method development and validation using Liquid Chromatography with tandem mass spectrometry (LC/MS), High Performance Liquid Chromatography (HPLC) and Ultra Performance Liquid Chromatography (UPLC), immunoassay (including the ultrasensitive Quanterix SIMOA® platform) and quantitative polymerase chain reaction (qPCR).
LC/MS is a powerful analytical technique that combines the separating power of liquid chromatography and triple quadrupole mass spectrometry to offer highly sensitive, selective measurements. Over the years, MicroConstants has served approximately 300 biotechnology and pharmaceutical companies to develop their products by providing high-quality work and deep expertise to support their clients’ drug development programs.
The second recent addition to the BioAgilytix family is 360biolabs®️. A world leader in virology expertise and located in Australia’s biomedical research hub, 360biolabs®️ has Biosafety Level (BSL) 2 & 3 laboratories, biomarker capabilities, and immunology support along with an expansive bioanalytical LC/MS small molecule suite.
With this transaction, BioAgilytix expands its global scope into the jurisdiction of choice for first-in-human trials (FIH) and early phase clinical trials. The acquisition joins 360biolabs®️ internationally recognized quality systems with BioAgilytix’s existing laboratories in Durham, North Carolina; Boston, MA; Hamburg, Germany; to create a comprehensive offering across all phases of pharmaceutical research.
Solidifying these professional partnerships worldwide allows BioAgilytix to continue growing in the US & European markets while increasing its global presence.
